BMS Forms Early-Stage Immunotherapy Pact
By

Bristol-Myers Squibb and the Moffitt Cancer Center have formed a collaboration as part of Bristol-Myers Squibb's Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the US. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.

As part of the I-O RPM program, Bristol-Myers Squibb and Moffitt will conduct a range of early-phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists.

The I-O RPM builds on Bristol-Myers Squibb's formation in 2012 of the International Immuno-Oncology Network (II-ON). II-ON is a global collaboration between Bristol-Myers Squibb and academia focused on facilitating the translation of scientific research findings into clinical trials and, eventually, clinical practice.

Source: Bristol-Myers Squibb

Leave a Reply

Your email address will not be published. Required fields are marked *